(Reuters) -Shares in Novo Nordisk rose 13.6% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

While the injections from Lilly and Novo have revolutionized the way obesity is treated, investors say pills are key to ...

Because chronic inflammation is key to aging, Ozempic’s anti-inflammatory effects (among others) make it a powerful ...